Results 11 to 20 of about 918,306 (202)
Long-term benefit of redo sympathetic renal denervation in a patient with resistant hypertension [PDF]
Advances in Interventional Cardiology, 2021 Sympathetic renal denervation (RDN) has been demonstrated as a potential treatment option for patients with resistant hypertension [1]. Despite discouraging results after the SYMPLICITY HTN-3 trial several techniques and catheters were introduced to the ...
Tomasz Tokarek +3 more
doaj +2 more sources
Percutaneous renal sympathetic denervation in catecholaminergic polymorphic ventricular tachycardia [PDF]
Journal of Arrhythmia, 2017 Catheter-based renal sympathetic denervation may be an alternative after unsuccessful conventional ablation attempts.
Tolga Aksu, MD, Erdem Guler, MD
doaj +2 more sources
Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension [PDF]
International Journal of Hypertension, 2011 Hypertension represents a major health problem with an appalling annual toll. Despite the plethora of antihypertensive drugs, hypertension remains resistant in a considerable number of patients, thus creating the need for alternative strategies ...
Vasilios Papademetriou +2 more
doaj +2 more sources
Renal sympathetic denervation in resistant hypertension [PDF]
World Journal of Cardiology, 2013 Resistant hypertension remains a major clinical problem despite the available multidrug therapy. Over the next decades, its incidence will likely increase given that it is strongly associated with older age and obesity. Resistant hypertension patients have an increased cardiovascular risk, thus effective antihypertensive treatment will provide ...
Mário, Santos, Henrique, Carvalho
openaire +4 more sources
Renal sympathetic denervation: renal nerve stimulation [PDF]
, 2019 This thesis is a collection of research regarding high blood pressure and renal sympathetic denervation. High blood pressure is a silent killer and a major risk factor for cardiovascular disease. Treatment of an elevated blood pressure can be achieved with medication. When medication fails and patients appear to suffer from drug resistant hypertension,
de Jong, Mark Roland, Mark de Jong
openaire +3 more sources
Renal Sympathetic Denervation for Treatment of Hypertension
Current Treatment Options in Cardiovascular Medicine, 2012 OPINION STATEMENT: Sympathetic nervous system activation of the heart, kidney and peripheral vasculature increases cardiac output, fluid retention and vascular resistance and plays an important role in acute and chronic BP elevation. Renal sympathetic denervation via a percutaneous radiofrequency catheter based approach is a safe and effective ...
Pimenta, Eduardo, Oparil, Suzanne
openaire +5 more sources
, 2016 This section provides a comprehensive procedural report for renal sympathetic denervation procedure with up-to-date explanatory notes, synopsis of the indications and contraindications and potential complications in an organized and practical format.
Sebaaly, Mikhael Georges +1 more
openaire +2 more sources
Short-term Safety and Efficiency of Cryoablation for Renal Sympathetic Denervation in a Swine Model
Chinese Medical Journal, 2015 Background: Renal sympathetic nerves are involved in the reflective activation of the sympathetic nervous system in circulatory control. Catheter-based renal denervation (RDN) ameliorated treatment-resistant hypertension safely, but 10%-20% of treated ...
Meng Ji +9 more
doaj +2 more sources
Renal sympathetic denervation in Sweden [PDF]
Journal of Hypertension, 2018 Renal denervation (RDN) is a catheter-based intervention to treat patients with resistant hypertension. The biological effects of RDN are not fully understood, and randomized controlled trials have generated conflicting evidence. This report presents data from the Swedish Registry for Renal Denervation, an investigator-driven nationwide registry.To ...
Sebastian, Völz +9 more
openaire +3 more sources
Renal Sympathetic Denervation for Hypertension. [PDF]
Kidney Int Rep, 2022 Arterial hypertension is the most prevalent global modifiable risk factor for cardiovascular morbidity and mortality. Despite the availability of numerous pharmacologic treatments, many patients do not achieve guideline-recommended blood pressure targets.
Guber K, Kirtane AJ.
europepmc +3 more sources